Last reviewed · How we verify
Human Neural Stem Cells
At a glance
| Generic name | Human Neural Stem Cells |
|---|---|
| Also known as | Human Neural Stem Cells Suspension |
| Sponsor | Casa Sollievo della Sofferenza IRCCS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant (PHASE1, PHASE2)
- Exercise in Patients Undergoing Autologous Stem Cell Transplantation: A Randomized Controlled Trial (NA)
- Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease (PHASE1, PHASE2)
- Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) (PHASE3)
- Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation (NA)
- The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders (PHASE1)
- The Safety and Efficacy of NouvSoma001 in Ischemic Stroke (PHASE1)
- A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Neural Stem Cells CI brief — competitive landscape report
- Human Neural Stem Cells updates RSS · CI watch RSS
- Casa Sollievo della Sofferenza IRCCS portfolio CI